Exemestane may be less detrimental than letrozole to bone health in women homozygous for the UGT2B17*2 gene deletion

PURPOSE: UGT2B17 gene deletion (UGT2B17*2) has been reported to affect bone health as well as the pharmacokinetics of aromatase inhibitor (AI) drugs such as exemestane. The goal of this study was to assess associations between UGT2B17 gene deletion and bone health prior to and after 24 months of AI...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Breast Cancer Res Treat
Hauptverfasser: Kamdem, Landry K., Xi, Jingyue, Clark, Brandi L., Gregory, Bryana J., Kidwell, Kelley M., Storniolo, Ana-Maria, Stearns, Vered, Hayes, Daniel F, Gersch, Christina L., Rae, James M., Henry, N. Lynn, Hertz, Daniel L.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2019
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6534458/
https://ncbi.nlm.nih.gov/pubmed/30747308
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-019-05158-3
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge